Tekmira: an important upcoming catalyst from ALN-TTR02
While Tekmira (TKMR) is making every effort to advance its own pipeline such as PLK1 and Ebola, investors may forget catalysts from the company's partnered programs. One important upcoming event will be the data release of ALN-TTR02 Phase II trial from partner Alnylam (ALNY) at the Peripheral Nerve Society Meeting in France on June 30, 2013.
As a reminder, Tekmira has granted a license to Alnylam Pharmaceuticals, Inc. to use Tekmira's lipid nanoparticle (LNP) technology to enable RNAi therapeutic products. Tekmira will receive milestone and royalty payments as these LNP-enabled products are developed and commercialized. ALNY is developing three RNAi therapeutics using Tekmira's LNP technology.
Alnylam has guided...